Mandaviya urges bulk drug manufacturers to invest more in research

The chemicals and fertilizers minister, who also holds the health portfolio, praised the industry players for playing a pivotal role during Covid times, not only domestically but also globally

Topics


Mansukh Lal Mandaviya | drug manufacturers | Drug makers in India

Union Minister Mansukh Mandaviya on Friday complimented the bulk drug manufacturers for making efforts towards making the country self-reliant in the sector and also urged them to invest more in research for making the industry competitive globally.

The minister, in a virtual event, emphasised that the pharmaceutical sector in India, besides being a business venture, is also a sector of social and strategic importance, the Ministry of Chemicals and Fertilizers said in a statement.

The chemicals and fertilizers minister, who also holds the health portfolio, praised the industry players for playing a pivotal role during COVID times, not only domestically but also globally.

During the meeting, he urged the industry to invest in the area of research and innovation for sustainable global competitiveness by allocating adequate resources.

The government had announced a production linked incentive (PLI) scheme for bulk drugs in March 2020 to attain self-reliance in identified critical drugs.

Till date, 49 projects have been approved for 33 critical APIs with a committed investment of Rs 3,685 crore.

Out of the 49 projects, 8 projects with investment of Rs 335 crore and with an annual production capacity of 16,021 MT have been commissioned as on date, the ministry said.

Further, 12 projects with committed investment of Rs 504 crore and having annual production capacity of 18,614 MT are in advanced stage of completion for commercial production. They are expected to be completed by March 31, 2022, it added.

Representatives from Centrient Pharmaceuticals India, Meghmani LLP, Emmennar Pharma, Andhra Organics, Hetero Group, Sadhana Nitro Chem and Sreepathi Pharmaceuticals attended the event.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor